| dc.description.abstract | Kint3-4 protein, originated from a genetic recombination of K1-3 and K1-4 human plasminogen segments, is recognized for its antiangiogenic and anti-inflammation potentiality. This study aims to evaluate the effect of Kint3-4 protein in tumor development in Swiss mice previously inoculated with Ehrlich tumor cells. Three different protocols were evaluated at the beginning, progression and stabilization of tumor growth. We evaluated tumor growth, histomorphological and immunohistochemical characteristics for CDC47 (cellular proliferation marker) and CD31 (blood vessel marker). Animals treated with Kint3-4 protein at the beginning andduring neoplastic progression, showed lower tumor growth, with smaller inflammation and tumor areas by histological evaluation. In all established protocols, lower rate of tumor cell proliferation and lower microvessel density was observed in animals treated with Kint3-4 protein. The participation of Kint3-4 recombinant protein in controllingtumor angiogenesis and malignant cell proliferation, as well as elucidation of molecular mechanisms of Kint3-4 protein would open prospects for its use in clinical and antiangiogenic therapy. | |
